MX369840B - Nuevos compuestos derivados de 6, 7-dihidro-3h-oxazolo [3, 4-a] pirazina-5, 8-diona. - Google Patents
Nuevos compuestos derivados de 6, 7-dihidro-3h-oxazolo [3, 4-a] pirazina-5, 8-diona.Info
- Publication number
- MX369840B MX369840B MX2016010912A MX2016010912A MX369840B MX 369840 B MX369840 B MX 369840B MX 2016010912 A MX2016010912 A MX 2016010912A MX 2016010912 A MX2016010912 A MX 2016010912A MX 369840 B MX369840 B MX 369840B
- Authority
- MX
- Mexico
- Prior art keywords
- novel
- oxazolo
- pyrazine
- dihydro
- compounds
- Prior art date
Links
- -1 6,7-dihydro-3h-oxazolo[3,4-a]pyrazine-5,8-dione derivative compounds Chemical class 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- SPNMSIYOCYTIIH-UHFFFAOYSA-N 6,7-dihydro-3h-[1,3]oxazolo[3,4-a]pyrazine-5,8-dione Chemical class O=C1CNC(=O)C2=COCN12 SPNMSIYOCYTIIH-UHFFFAOYSA-N 0.000 abstract 1
- 208000010228 Erectile Dysfunction Diseases 0.000 abstract 1
- 229940123333 Phosphodiesterase 5 inhibitor Drugs 0.000 abstract 1
- 102000004861 Phosphoric Diester Hydrolases Human genes 0.000 abstract 1
- 108090001050 Phosphoric Diester Hydrolases Proteins 0.000 abstract 1
- 239000002249 anxiolytic agent Substances 0.000 abstract 1
- 229940082638 cardiac stimulant phosphodiesterase inhibitors Drugs 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 201000001881 impotence Diseases 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 239000002590 phosphodiesterase V inhibitor Substances 0.000 abstract 1
- 239000002571 phosphodiesterase inhibitor Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/424—Oxazoles condensed with heterocyclic ring systems, e.g. clavulanic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/04—Drugs for disorders of the urinary system for urolithiasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Urology & Nephrology (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Pulmonology (AREA)
- Gynecology & Obstetrics (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
La presente invención se refiere a nuevos derivados de 6,7-dihidro-3H-oxazolo[3,4-a]pirazina-5,8-diona o a una mezcla de éstos. La presente invención también contempla composiciones farmacéuticas que comprendan una cantidad eficaz de uno de los nuevos compuestos que son objeto de la presente invención, así como el uso de dichos compuestos y/o derivados como inhibidores de enzimas fosfodiesterasas y el uso de los compuestos y/o derivados en el tratamiento de la disfunción eréctil, de trastornos y/o condiciones tratables con relajación de tejidos y de trastornos tratables con inhibidores de fosfodiesterasas, más específicamente con inhibidores de la PDE-5. Un objetivo adicional de la presente invención es proveer un medicamento que comprenda una cantidad terapéuticamente eficaz de uno de los nuevos compuestos y un método de tratamiento utilizando dichos nuevos compuestos.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201461943825P | 2014-02-24 | 2014-02-24 | |
| PCT/BR2015/000023 WO2015123748A1 (pt) | 2014-02-24 | 2015-02-24 | "NOVOS COMPOSTOS DERIVADOS DE 6,7-DIHIDRO-3H-OXAZOLO [3,4-a] PIRAZINA-5,8-DIONA " |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2016010912A MX2016010912A (es) | 2016-11-30 |
| MX369840B true MX369840B (es) | 2019-11-22 |
Family
ID=53877456
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2016010912A MX369840B (es) | 2014-02-24 | 2015-02-24 | Nuevos compuestos derivados de 6, 7-dihidro-3h-oxazolo [3, 4-a] pirazina-5, 8-diona. |
Country Status (19)
| Country | Link |
|---|---|
| US (1) | US9359378B2 (es) |
| EP (1) | EP3133072B1 (es) |
| JP (1) | JP6636463B2 (es) |
| KR (1) | KR102408431B1 (es) |
| AR (1) | AR099523A1 (es) |
| AU (1) | AU2015221431B2 (es) |
| BR (1) | BR112016019609B1 (es) |
| CA (1) | CA2940225C (es) |
| CL (1) | CL2016002125A1 (es) |
| ES (1) | ES2734063T3 (es) |
| HU (1) | HUE044993T2 (es) |
| IL (1) | IL247330B (es) |
| MX (1) | MX369840B (es) |
| PL (1) | PL3133072T3 (es) |
| PT (1) | PT3133072T (es) |
| TR (1) | TR201910896T4 (es) |
| UY (1) | UY36010A (es) |
| WO (1) | WO2015123748A1 (es) |
| ZA (1) | ZA201606522B (es) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20220296590A1 (en) * | 2019-07-15 | 2022-09-22 | Biolab Sanus Farmaceutica Ltda | Stereoisomers of the compound 3-(benzo[d][1,3]dioxol-5-yl)-7-(1-hydroxypropan-2-yl)-1-(1h-indol-3-yl)-6,7-dihydro-3h-oxazol[3,4-a]pyrazine-5,8-dione and use thereof as an antitumor agent and phosphodiesterase enzyme inhibitor |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7098209B2 (en) * | 2001-06-05 | 2006-08-29 | Lilly Icos Llc | Pyrazino [1'2':1,6 ] pyrido [3, 4-b] indole-1,4-dione derivatives |
| AR045950A1 (es) * | 2003-10-09 | 2005-11-16 | Speedel Experimenta Ag | Compuestos derivados de piperazina, composiciones farmaceuticas que los contienen y su uso en la fabricacion de medicamentos. |
| AR073522A1 (es) * | 2008-09-30 | 2010-11-10 | Biolab Sanus Farmaceutica Ltda | Compuestos derivados de 2-(3-metilenodioxi) - benzoil indol |
| BRPI0903803B1 (pt) * | 2009-09-30 | 2019-07-09 | Biolab Sanus Farmacêutica Ltda. | Composto, processo de preparação, composição farmacêutica e uso dos compostos |
| UY33535A (es) * | 2010-08-13 | 2011-12-01 | Biolab Sanus Farmaceutuca Limitada | Derivados de 6,7-dihidro-3h-oxazolo[3,4]pirazin-5,8-diona |
-
2015
- 2015-02-23 AR ARP150100529A patent/AR099523A1/es active IP Right Grant
- 2015-02-24 MX MX2016010912A patent/MX369840B/es active IP Right Grant
- 2015-02-24 AU AU2015221431A patent/AU2015221431B2/en active Active
- 2015-02-24 JP JP2016570147A patent/JP6636463B2/ja active Active
- 2015-02-24 KR KR1020167026361A patent/KR102408431B1/ko active Active
- 2015-02-24 TR TR2019/10896T patent/TR201910896T4/tr unknown
- 2015-02-24 WO PCT/BR2015/000023 patent/WO2015123748A1/pt not_active Ceased
- 2015-02-24 BR BR112016019609-0A patent/BR112016019609B1/pt active IP Right Grant
- 2015-02-24 PL PL15752140T patent/PL3133072T3/pl unknown
- 2015-02-24 HU HUE15752140 patent/HUE044993T2/hu unknown
- 2015-02-24 PT PT15752140T patent/PT3133072T/pt unknown
- 2015-02-24 CA CA2940225A patent/CA2940225C/en active Active
- 2015-02-24 ES ES15752140T patent/ES2734063T3/es active Active
- 2015-02-24 UY UY0001036010A patent/UY36010A/es active IP Right Grant
- 2015-02-24 EP EP15752140.2A patent/EP3133072B1/en active Active
- 2015-02-24 US US14/630,410 patent/US9359378B2/en active Active
-
2016
- 2016-08-17 IL IL247330A patent/IL247330B/en active IP Right Grant
- 2016-08-23 CL CL2016002125A patent/CL2016002125A1/es unknown
- 2016-09-21 ZA ZA2016/06522A patent/ZA201606522B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| MX2016010912A (es) | 2016-11-30 |
| ES2734063T3 (es) | 2019-12-04 |
| KR20160116028A (ko) | 2016-10-06 |
| US9359378B2 (en) | 2016-06-07 |
| CA2940225A1 (en) | 2015-08-27 |
| EP3133072B1 (en) | 2019-05-01 |
| AU2015221431A8 (en) | 2016-11-24 |
| CA2940225C (en) | 2021-12-28 |
| PL3133072T3 (pl) | 2019-10-31 |
| KR102408431B1 (ko) | 2022-06-13 |
| AU2015221431A1 (en) | 2016-09-29 |
| JP6636463B2 (ja) | 2020-01-29 |
| CL2016002125A1 (es) | 2016-12-30 |
| ZA201606522B (en) | 2018-04-25 |
| AU2015221431B2 (en) | 2018-04-19 |
| US20150239903A1 (en) | 2015-08-27 |
| WO2015123748A1 (pt) | 2015-08-27 |
| AR099523A1 (es) | 2016-07-27 |
| BR112016019609A2 (es) | 2017-08-22 |
| EP3133072A1 (en) | 2017-02-22 |
| JP2017506263A (ja) | 2017-03-02 |
| EP3133072A4 (en) | 2017-08-09 |
| UY36010A (es) | 2015-09-30 |
| IL247330A0 (en) | 2016-09-29 |
| BR112016019609B1 (pt) | 2022-06-14 |
| IL247330B (en) | 2020-10-29 |
| TR201910896T4 (tr) | 2019-08-21 |
| HUE044993T2 (hu) | 2019-11-28 |
| PT3133072T (pt) | 2019-07-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2023004037A (es) | Compuestos biciclicos como inhibidores alostericos de shp2. | |
| EA202091709A1 (ru) | Ингибиторы днк-пк | |
| EA202091708A1 (ru) | Ингибиторы днк-пк | |
| PH12019550050A1 (en) | Isoxazole analogs as fxr agonists and methods of use thereof | |
| PH12019500521A1 (en) | Pyrazolopyridine derivatives as hpk1 modulators and uses thereof for the treatment of cancer | |
| SG10201909545XA (en) | Bile acid derivatives as fxr/tgr5 agonists and methods of use thereof | |
| MY192717A (en) | Bile acid derivatives as fxr/tgr5 agonists and methods of use thereof | |
| MX2017017097A (es) | Macrociclos diarílicos quirales como moduladores de proteínas quinasas. | |
| MD4800B1 (ro) | Compuşi de aminopirimidinil ca inhibitori de JAK | |
| MY193524A (en) | Diaryl macrocycles as modulators of protein kinases | |
| PH12018501084A1 (en) | Heterocyclic compounds as immunomodulators | |
| MX2017004618A (es) | Inhibidores de la biosintesis de sulfato de heparano para el tratamiento de enfermedades. | |
| PH12017502260A1 (en) | Tricyclic compounds and their use as phosphodiesterase inhibitors | |
| EA201692313A1 (ru) | Производные индолизина в качестве ингибиторов фосфоинозитид-3-киназ | |
| PH12017500841B1 (en) | 2-amino-6-(difluoromethyl)- 5,5-difluoro-6-phenyl-3,4,5,6-tetrahydropyridines as bace1 inhibitors | |
| EA033238B1 (ru) | Новые производные тиенопиримидина в качестве ингибиторов nik | |
| PH12017501043A1 (en) | 2-amino-5,5-difluoro-6-(fluoromethyl)-6-phenyl-3,4,5,6-tetrahydropyridines as bace1 inhibitors | |
| PH12017500089A1 (en) | Aldosterone synthase inhibitors | |
| PH12017500595A1 (en) | Aldosterone synthase inhibitors | |
| MX2019006863A (es) | Inhibidores de heparanasa y uso de los mismos. | |
| MX376090B (es) | Derivados de cromeno como inhibidores de las fosfoinositido-3-cinasas. | |
| MX2017008083A (es) | Compuestos 2,3,4,5-tetrahidropiridin-6-amina y 3,4-dihidro-2h-pirrol-5-amina inhibidores de beta-secretasa. | |
| MX395492B (es) | Usos terapeuticos de l-4 cloroquinurenina. | |
| MX2019010218A (es) | Derivados de pirazol como inhibidores de bromodominio. | |
| MX2018007517A (es) | Compuestos triciclicos y composiciones como inhibidores de quinasa. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant or registration |